The anticonvulsant effects of the enantiomers of losigamone

British Journal of Pharmacology

Volumn 128, Issue 6, 1999, Pages 1223-1228

  Jones, Francis A ^a   Davies, John A ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

Amino acid release; Anticonvulsants; Audiogenic seizures; Brain slices; Losigamone enantiomers

Indexed keywords

AMINO ACID; ANTICONVULSIVE AGENT; ASPARTIC ACID; GLUTAMIC ACID; LOSIGAMONE; POTASSIUM; VERATRIDINE;

AMINO ACID TRANSPORT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTICONVULSANT ACTIVITY; ARTICLE; AUDIOGENIC SEIZURE; BRAIN SLICE; CEREBROSPINAL FLUID; CLINICAL TRIAL; CLONIC SEIZURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPOLARIZATION; DOSE RESPONSE; ENANTIOMER; GRAND MAL SEIZURE; HUMAN; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; MOUSE; NONHUMAN; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; TONIC SEIZURE;

EID: 0032754438     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjp.0702919     Document Type: Article

References (23)

1. BARNES, S., LEIGHTON, G.E. & DAVIES, J.A. (1988). A novel superfusion system for the measurement of endogenous glutamate release from cerebellar slices. J. Neurosci. Meth., 23, 57-61.
2. CHATTERJEE, S.S. & NOLDNER, M. (1997). Losigamone: From plant extract to antiepileptic drug. CNS Drug Rev., 3, 225-244.
3. DICKIE, B.G.M. & DAVIES, J.A. (1992). Calcium blocking agents and potassium-stimulated release of glutamate from cerebellar slices. Eur. J. Pharmacol., 229, 97-99.
4. A-receptor system. Epilepsia, 36, 983-989.
5. HAUSER, W.A. & ANNEGERS, J.F. (1993). Epidemiology of epilepsy. In: Laidlaw, J., Richen, A. & Chadwick, D. (eds). Textbook of epilepsy. Churchill Livingstone: Edinburgh, 23-45.
6. HU, R.Q. & DAVIES, J.A. (1995). The effects of the desglycinyl metabolite of remacemide on cortical wedges prepared from DBA/2 mice. Eur. J. Pharmacol., 287, 251-256.
7. HUNTLEY, G.W., VICAR, J.C. & MORRISON, J.H. (1994). Cellular and synaptic localisation of NMDA and non-NMDA receptor subunits in neocortex: organisational features related to cortical circuitry, function and disease. Trends Neurosci., 17, 536-543.
8. KAPETANOVIC, I.M., YONEKAWA, W.D. & KUPFENBERG, H.J. (1995). The effects of anticonvulsant compounds on 4-aminopyridine-induced de novo synthesis of neurotransmitter amino acids in rat hippocampus in vitro. Epilepsy Res., 20, 113-120.
9. LEACH, M.J., MARDEN, C.M. & MILLER, A.A. (1986). Pharmacological studies on lamotrigine, a novel potential antiepileptic drug: II. Neurochemical studies on the mechanism of action. Epilepsia, 27, 490-497.
10. LEVI, G., GALLO, V. & RAITERI, M. (1980). A re-evaluation of veratridine as a tool for studying the depolarization-induced release of neurotransmitter from nerve endings. Neurochem. Res., 5, 281-295.
11. LOSCHER, W. (1993). Basic aspects of epilepsy. Curr. Opin. Neurol. Neurosurg., 6, 223-232.
12. MICHIN, M.C.W. (1980). Veratrum alkaloids as transmitter releasing agents. J. Neurosci. Meth., 2, 111-112.
13. RICHENS, A. & PERUCCA, E. (1993). In: Textbook of epilepsy. Laidlaw, J., Richens, A. & Chadwick, D. (eds). Churchill Livingstone: Edinburgh, 495-559.
14. ROWLEY, H.L., ELLIS, Y. & DAVIES, J.A. (1993). Age-related effects of NMDA-stimulated concomitant release of nitric oxide and glutamate in cortical slices prepared from DBA/2 mice. Brain Res., 613, 49-53.
15. SANDER, J.W.A.S. (1998). New drugs for epilepsy. Curr. Opin. Neurol., 11, 141-148.
16. SCHMITZ, D., GLOVELLI, T. & HEINEMANN, U. (1995). Effect of losigamone on synaptic potentials and spike frequency habituation in rat entorhinal cortex and hippocampal CA1 neurones. Neurosci. Lett., 200, 141-143.
17. INIVASAN, J., RICHENS, A. & DAVIES, J.A. (1995). The effect of the desglycinyl metabolite of remacemide hydrochloride (FPL 12495AA) and dizocilpine (MK-801) on endogenous amio acid release from mouse cortex. Br. J. Pharmacol., 116, 3087-3092.
18. INIVASAN, J., RICHENS, A. & DAVIES, J.A. (1997). The effects of losigamone (AO-33) on electrical activity and excitatory amino acid release in mouse cortical slices. Br. J. Pharmacol., 122, 1490-1494.
19. STEIN, U. (1995). Losigamone. In: Antiepileptic Drugs. Levy, R.H., Mattson, R.H. & Meldrum, B.S. (eds). Raven Press: New York, 1025-1034.
20. STEIN, U., KLESSING, K. & CHATTERJEE, S.S. (1991). Losigamone. In: Pisani, F., Perucca, E., Avanzini, G. & Richens, A. (eds). New antiepileptic drugs. (Epilepsy Res. suppl. 3). Elsevier: Amsterdam, 129-133.
21. TORCHIN, C.D., MCNEILLY, P.J., KAPTENOVIC, I.M., STRONG, J.M., HARVEY, J.K. (1996). Stereoselective metabolism of a new anticonvulsant drug candidate, Losigamone, by human liver microsomes. Drug. Metab. and Disp., 24, 1002-1008.
22. TURNELL, D.C. & COOPER, J.D.H. (1981). Rapid assay for amino acids in serum or urine by pre-column derivatization and reverse-phase liquid chromatography. Clin. Chem., 28, 527-531.
23. ZHANG, C.L., CHATTERJEE, S.S., STEIN, U. & HEINEMANN, U. (1992). Comparison of the effect of losigamone and its isomers on maximal electroshock-induced convulsions in mice and on three different patterns of low-magnesium-induced epileptiform activity in slices of rat temporal cortex. Naunyn-Schmiedeberg's Arch. Pharmacol., 345, 85-92.